Chronic Lymphocytic Leukemia Clinical Trials in Goldsboro, North Carolina

4 studies are recruiting for chronic lymphocytic leukemia in Goldsboro, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymph…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina
    Locations
    632 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT04269902 on ClinicalTrials.gov

  2. A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

    The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib i…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Southeastern Medical Oncology Center ( Site 0049), Goldsboro, North Carolina
    Locations
    203 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06136559 on ClinicalTrials.gov

  3. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the earl…

    Stage
    Not phased
    Ages
    40 to 75
    Site
    Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina
    Locations
    745 in total
    Run by
    Alliance for Clinical Trials in Oncology

    See if you can join NCT05334069 on ClinicalTrials.gov

  4. A Long-term Extension Study of PCI-32765 (Ibrutinib)

    The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively rece…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Southeastern Medical Oncology Center, Goldsboro, North Carolina
    Locations
    175 in total
    Run by
    Janssen Research & Development, LLC

    See if you can join NCT01804686 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.